3-Month vs 12-Month DAPT After ACS: The DUAL-ACS Trial

3-Month vs 12-Month DAPT After ACS: The DUAL-ACS Trial

The DUAL-ACS trial demonstrated that 3-month dual antiplatelet therapy (DAPT) after acute coronary syndrome (ACS) suggested a trend toward reduced risk of all-cause death and major bleeding compared with 12-month DAPT, according to a study presented by Dr. David Newby, University of Edinburgh, UK, in the Hot Line session at ESC Congress 2025.

Currently, both the ESC and AHA/ACC guidelines recommend continuing DAPT for at least 12 months in A...
Continue reading this article
Select an option below:
Go beyond the guidelines
A portal site of complex catheter intervention techniques
About TCROSS NEWS Global

TCROSS NEWS Global is an online medical journal that provides valuable information on Cardiovascular medicine to medical professionals worldwide.
We bring you the latest findings and trends in all areas of cardiovascular medicine. Please register and subscribe for unlimited access to quality Cardiovascular News!

Introducing the main contents
Conference Reports
Conference Reports
Timely delivery of scientific meetings from around the world, including AHA, ESC, TCT, EuroPCR, JCC, etc!
Complex PCI Cases
Complex PCI Cases
Features case reports on patients with complex lesions encountered in daily clinical practice.
Live Demonstration Courses
Live Demonstration CoursesComing soon
In this section you will find live videos of catheter interventions for complex lesions.
What is TCROSS NEWS GLOBAL?
TCROSS NEWS Global, an affiliate of TCROSS Co., Ltd. Japan(established in 2005) is a cardiovascular news website which serves as a link between cardiologists, medical device manufacturers and industry stakeholders.
We provide timely and up-to-date information to our partners across the world by covering and reporting live sessions and conferences, featuring of complex cases, newsletters, academic researches and case studies.
Learn more about TCROSS NEWS Global
This website is automatically translated using Google Translate.

Recommendations

Inclisiran-based Strategy Versus Individually Optimized Lipid-lowering Therapy: The VICTORION-Difference Study
Inclisiran-based Strategy Versus Individually Optimized Lipid-lowering Therapy: The VICTORION-Difference Study
ESC 2025
Tailored Antiplatelet Therapy in High-Risk Patients Undergoing Complex PCI: The TAILORED-CHIP Trial
Tailored Antiplatelet Therapy in High-Risk Patients Undergoing Complex PCI: The TAILORED-CHIP Trial
ESC 2025
Timing of Complete Revascularization During Index Hospitalisation in Patients With STEMI and Multivessel Disease: The OPTION-STEMI Trial
Timing of Complete Revascularization During Index Hospitalisation in Patients With STEMI and Multivessel Disease: The OPTION-STEMI Trial
ESC 2025
Early Aspirin Discontinuation Following PCI in Low-Risk Acute MI Patients: The TARGET FIRST Trial
Early Aspirin Discontinuation Following PCI in Low-Risk Acute MI Patients: The TARGET FIRST Trial
ESC 2025
PICK UP
Challenging Healthcare Marketing Costs toward Achieving Universal Health Coverage
Special
InsighTCROSS
CIAT 2025 in Thailand – Call for Abstracts and Cases
Other
CIAT 2025 in Thailand – Call for Abstracts and Cases
Early Aspirin Discontinuation vs DAPT After PCI in Patients With ACS: The NEO-MINDSET Trial
ESC 2025
Early Aspirin Discontinuation vs DAPT After PCI in Patients With ACS: The NEO-MINDSET Trial
Assessment of Quitting versus Using Aspirin Therapy In Patients with Stabilized Coronary Artery Disease after Stenting who Require Long-term Oral Anticoagulation: The AQUATIC Trial
ESC 2025
Assessment of Quitting versus Using Aspirin Therapy In Patients with Stabilized Coronary Artery Disease after Stenting who Require Long-term Oral Anticoagulation: The AQUATIC Trial
Effect of Drug-Coated Devices in Patients with CLTI and Intermittent Claudication: The SWEDEPAD Trial
ESC 2025
Effect of Drug-Coated Devices in Patients with CLTI and Intermittent Claudication: The SWEDEPAD Trial
ESC Congress 2025 Closes with 33,000 Participants and 484 Presentations from Japan
ESC 2025
ESC Congress 2025 Closes with 33,000 Participants and 484 Presentations from Japan